Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

Arizona couple Michael and Julie Carroll have lost a combined 177 lbs. on a GLP-1 weight loss drug. 'It gave me my ...

Michael Carroll didn't go out in public and couldn't put on his own socks. Then he and wife Julie began taking a GLP-1 ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

According to the study, participants taking Zepbound lost an average of 20.2% of their starting weight after 72 weeks, ...

The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 484.64% and ...

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

Cases of a bacterial infection called "rabbit fever" have been increasing during the past decade, according to the U.S.